Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Urick Paul
 2. Date of Event Requiring Statement (Month/Day/Year)
11/01/2016		 3. Issuer Name and Ticker or Trading Symbol
Diplomat Pharmacy, Inc. [DPLO]
(Last)
(First)
(Middle)
C/O DIPLOMAT PHARMACY, INC., 4100 SOUTH SAGINAW STREET		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
President
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

FLINT, MI 48507		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 3,194
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option to Acquire Common Stock   (1) 06/19/2025 Common Stock 100,000 $ 44.39 D  
Employee Stock Option to Acquire Common Stock   (2) 07/10/2025 Common Stock 33,448 $ 48.64 D  
Employee Stock Option to Acquire Common Stock   (3) 01/27/2026 Common Stock 50,000 $ 29.95 D  
Employee Stock Option to Acquire Common Stock   (4) 02/12/2026 Common Stock 25,000 $ 29.73 D  
Employee Stock Option to Acquire Common Stock   (5) 03/21/2026 Common Stock 14,961 $ 25.92 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Urick Paul
C/O DIPLOMAT PHARMACY, INC.
4100 SOUTH SAGINAW STREET
FLINT, MI 48507		       President  

Signatures

Jeffrey H. Kuras, Attorney-in-fact 11/01/2016
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The options were granted on June 19, 2015. The options began to vest in annual increments of 25% of the option grant on the one-year anniversary of the grant date, to be fully vested after four years. 25% of the options originally granted are currently vested and exercisable.
(2) The options were granted on July 10, 2015. The options began to vest in annual increments of 25% of the option grant on the one-year anniversary of the grant date, to be fully vested after four years. 25% of the options originally granted are currently vested and exercisable.
(3) The options were granted on January 27, 2016. The options will begin to vest in annual increments of 25% of the option grant on the one-year anniversary of the grant date, to be fully vested after four years.
(4) The options were granted on February 12, 2016. The options will begin to vest in annual increments of 25% of the option grant on the one-year anniversary of the grant date, to be fully vested after four years.
(5) The options were granted on March 21, 2016, and vest according to certain financial performance criteria of the Company. To the extent such criteria are met, the options will vest in annual increments of 25% of the option grant beginning on March 31, 2017, to be fully vested after four years.
 
Remarks:
Exhibit 24, Power of Attorney, is attached.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.